PIPERACILLIN AND TAZOBACTAM

Piperacillin And Tazobactam Adverse Events Reported to the FDA Over Time

How are Piperacillin And Tazobactam adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Piperacillin And Tazobactam, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Piperacillin And Tazobactam is flagged as the suspect drug causing the adverse event.

Most Common Piperacillin And Tazobactam Adverse Events Reported to the FDA

What are the most common Piperacillin And Tazobactam adverse events reported to the FDA?

Renal Failure Acute	142 (2.31%)
Pyrexia	123 (2%)
Thrombocytopenia	105 (1.71%)
Rash	86 (1.4%)
Pruritus	66 (1.07%)
Condition Aggravated	64 (1.04%)
Drug Rash With Eosinophilia And Sys...	63 (1.02%)
Neutropenia	61 (.99%)
Rash Maculo-papular	61 (.99%)
Drug Interaction	58 (.94%)
Rash Erythematous	57 (.93%)
	Show More
Pancytopenia	55 (.89%)
Stevens-johnson Syndrome	55 (.89%)
Death	54 (.88%)
Sepsis	54 (.88%)
Septic Shock	53 (.86%)
Paraesthesia	50 (.81%)
Alanine Aminotransferase Increased	49 (.8%)
Hypotension	48 (.78%)
Agranulocytosis	47 (.76%)
Drug Ineffective	46 (.75%)
Renal Failure	46 (.75%)
Eosinophilia	45 (.73%)
Multi-organ Failure	43 (.7%)
Leukopenia	42 (.68%)
Cholestasis	41 (.67%)
Tachycardia	39 (.63%)
Aspartate Aminotransferase Increase...	38 (.62%)
Dyspnoea	38 (.62%)
Erythema	38 (.62%)
Cytolytic Hepatitis	36 (.58%)
Encephalopathy	35 (.57%)
Toxic Epidermal Necrolysis	35 (.57%)
Diarrhoea	34 (.55%)
Acute Respiratory Distress Syndrome	32 (.52%)
Clostridium Difficile Colitis	32 (.52%)
Blood Creatinine Increased	30 (.49%)
Pneumonia	30 (.49%)
Anaphylactic Reaction	28 (.45%)
Dermatitis Exfoliative	28 (.45%)
Hepatotoxicity	28 (.45%)
Tubulointerstitial Nephritis	28 (.45%)
Clostridial Infection	27 (.44%)
Liver Function Test Abnormal	27 (.44%)
Renal Impairment	27 (.44%)
Skin Warm	27 (.44%)
Blood Alkaline Phosphatase Increase...	26 (.42%)
Drug Hypersensitivity	26 (.42%)
Hepatic Failure	26 (.42%)
Toxic Skin Eruption	25 (.41%)
Cardio-respiratory Arrest	24 (.39%)
Platelet Count Decreased	24 (.39%)
White Blood Cell Count Decreased	24 (.39%)
Anaemia	23 (.37%)
Chills	23 (.37%)
Coma	23 (.37%)
Confusional State	23 (.37%)
Renal Tubular Necrosis	23 (.37%)
Haemoglobin Decreased	22 (.36%)
Respiratory Failure	22 (.36%)
Hepatic Function Abnormal	21 (.34%)
Petechiae	21 (.34%)
Staphylococcal Infection	21 (.34%)
Dermatitis Bullous	20 (.32%)
Dialysis	20 (.32%)
Haemodialysis	20 (.32%)
Product Contamination Microbial	20 (.32%)
Blood Urea Increased	19 (.31%)
Bone Marrow Failure	19 (.31%)
Gamma-glutamyltransferase Increased	19 (.31%)
Haemolytic Anaemia	19 (.31%)
Rash Pruritic	19 (.31%)
Urticaria	19 (.31%)
Vomiting	19 (.31%)
Drug Toxicity	18 (.29%)
General Physical Health Deteriorati...	18 (.29%)
Lung Disorder	18 (.29%)
Pain	18 (.29%)
Pleural Effusion	18 (.29%)
Respiratory Distress	18 (.29%)
Abdominal Pain	17 (.28%)
Acute Generalised Exanthematous Pus...	17 (.28%)
Anuria	17 (.28%)
Blister	17 (.28%)
Bronchopulmonary Aspergillosis	17 (.28%)
Cardiac Arrest	17 (.28%)
Chest Pain	17 (.28%)
Blood Bilirubin Increased	16 (.26%)
Blood Lactate Dehydrogenase Increas...	16 (.26%)
Convulsion	16 (.26%)
Infection	16 (.26%)
Klebsiella Infection	16 (.26%)
Liver Disorder	16 (.26%)
Blood Pressure Decreased	15 (.24%)
Febrile Neutropenia	15 (.24%)
Hypokalaemia	15 (.24%)
Myoclonus	15 (.24%)
Nausea	15 (.24%)
Purpura	15 (.24%)
White Blood Cell Count Increased	15 (.24%)
Dehydration	14 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Piperacillin And Tazobactam, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Piperacillin And Tazobactam is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Piperacillin And Tazobactam

What are the most common Piperacillin And Tazobactam adverse events reported to the FDA?

Epidermal And Dermal Conditions	746 (12.12%)
Hepatic And Hepatobiliary	288 (4.68%)
Renal Disorders	277 (4.5%)
Infections - Pathogen Unspecified	273 (4.44%)
White Blood Cell	234 (3.8%)
Bacterial Infectious	214 (3.48%)
Neurological	199 (3.23%)
Hepatobiliary	168 (2.73%)
Hematology Investigations	162 (2.63%)
Respiratory	154 (2.5%)
Therapeutic And Nontherapeutic Effe...	146 (2.37%)
	Show More
Cardiac Arrhythmias	142 (2.31%)
Body Temperature Conditions	134 (2.18%)
Anemias Nonhemolytic And Marrow Dep...	124 (2.01%)
Platelet	124 (2.01%)
Lower Respiratory Tract Disorders	106 (1.72%)
Allergic Conditions	93 (1.51%)
Renal And Urinary Tract Investigati...	73 (1.19%)
Nephropathies	70 (1.14%)
Decreased And Nonspecific Blood Pre...	69 (1.12%)
Gastrointestinal Signs	66 (1.07%)
Fatal Outcomes	58 (.94%)
Fungal Infectious	58 (.94%)
Electrolyte And Fluid Balance Condi...	57 (.93%)
Gastrointestinal Motility And Defec...	54 (.88%)
Cardiac And Vascular Investigations	51 (.83%)
Skin Vascular Abnormalities	50 (.81%)
Enzyme	49 (.8%)
Hematological And Lymphoid Tissue T...	45 (.73%)
Encephalopathies	44 (.71%)
Seizures	42 (.68%)
Product Quality Issues	38 (.62%)
Deliria	37 (.6%)
Oral Soft Tissue Conditions	37 (.6%)
Central Nervous System Vascular	33 (.54%)
Procedural And Device Related Injur...	33 (.54%)
Angiedema And Urticaria	32 (.52%)
Coagulopathies And Bleeding Diathes...	31 (.5%)
Medication Errors	31 (.5%)
Hemolyses And Related Conditions	29 (.47%)
Muscle	29 (.47%)
Gastrointestinal Hemorrhages	28 (.45%)
Microbiology And Serology	28 (.45%)
Viral Infectious	27 (.44%)
Pleural	26 (.42%)
Toxicology And Therapeutic Drug Mon...	26 (.42%)
Cardiac Disorder Signs	24 (.39%)
Chemical Injury And Poisoning	24 (.39%)
Movement Disorders	24 (.39%)
Urinary Tract Signs	24 (.39%)
Vascular	24 (.39%)
Administration Site Reactions	22 (.36%)
Neuromuscular	22 (.36%)
Bronchial Disorders	21 (.34%)
Bile Duct	20 (.32%)
Physical Examination Topics	20 (.32%)
Anxiety Disorders	19 (.31%)
Disturbances In Thinking	19 (.31%)
Ocular Infections, Irritations And ...	18 (.29%)
Spleen, Lymphatic And Reticulendoth...	18 (.29%)
Water, Electrolyte And Mineral	18 (.29%)
Metabolic, Nutritional And Blood Ga...	17 (.28%)
Tongue Conditions	17 (.28%)
Injuries	16 (.26%)
Acid-base	15 (.24%)
Heart Failures	15 (.24%)
Peritoneal And Retroperitoneal Cond...	15 (.24%)
Gastrointestinal Ulceration And Per...	14 (.23%)
Glucose Metabolism Disorders	14 (.23%)
Musculoskeletal And Connective Tiss...	14 (.23%)
Appetite And General Nutritional	13 (.21%)
Headaches	13 (.21%)
Hematopoietic Neoplasms	13 (.21%)
Immunology And Allergy	13 (.21%)
Joint	13 (.21%)
Leukemias	13 (.21%)
Protein And Chemistry Analyses	13 (.21%)
Skin Appendage Conditions	13 (.21%)
Vascular Hypertensive	13 (.21%)
Vision	13 (.21%)
Ocular Neuromuscular	12 (.19%)
Peripheral Neuropathies	12 (.19%)
Upper Respiratory Tract Disorders	12 (.19%)
Vascular Hemorrhagic	12 (.19%)
Gallbladder	11 (.18%)
Skin And Subcutaneous Tissue	11 (.18%)
Neonatal And Perinatal Conditions	10 (.16%)
Exocrine Pancreas Conditions	9 (.15%)
Gastrointestinal Inflammatory Condi...	9 (.15%)
Immune	9 (.15%)
Protein And Amino Acid Metabolism	9 (.15%)
Coronary Artery	8 (.13%)
Gastrointestinal Vascular Condition...	8 (.13%)
Mental Impairment	8 (.13%)
Personality Disorders	8 (.13%)
Psychiatric	8 (.13%)
Congenital And Hereditary	7 (.11%)
Embolism And Thrombosis	7 (.11%)
Increased Intracranial Pressure And...	7 (.11%)
Lifestyle Issues	7 (.11%)
Myocardial	7 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Piperacillin And Tazobactam, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Piperacillin And Tazobactam is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.